(HealthDay)—Increasing adherence to evidence-based prophylaxis protocols for epidermal growth factor receptor inhibitor (EGFRi)-associated rash can reduce interventions and toxicity-associated chemotherapy interruptions, according to a study published online July 1 in JAMA Dermatology. Zizi Yu, from Harvard Medical School in Boston, and colleagues examined the impact of adherence to prophylaxis guidelines for prevention of EGFRi-associated cutaneous […]